YX0798是一种高效、选择性、口服有效的CDK9抑制剂用于治疗侵袭性淋巴瘤
本研究通过结构优化发现新型CDK9抑制剂YX0798,其具有显著靶点选择性和高亲和力,口服生物利用度良好。在临床前套细胞淋巴瘤模型中,口服YX0798(5 mg/kg每日)在体内产生有效抗肿瘤活性并克服治疗耐药。机制上,YX0798下调短寿命癌蛋白c-MYC和促生存蛋白MCL-1,破坏细胞周期并导致转录组重编程,最终引起细胞死亡。
要点
- YX0798是经结构优化发现的新型CDK9抑制剂,具有高靶点选择性和亲和力。
- 口服YX0798(5 mg/kg每日)在体内显示有效抗肿瘤活性并克服治疗耐药。
- YX0798下调c-MYC和MCL-1,破坏细胞周期并诱导转录组重编程导致细胞死亡。
核心结论
- YX0798具有口服生物利用度、优异选择性和通过驱动转录重编程走向肿瘤细胞杀伤的抗肿瘤效力。
研究设计与样本
- 临床前研究,通过结构优化发现YX0798,并在套细胞淋巴瘤(MCL)模型中进行体内外评价。
主要发现
- YX0798在结合CDK9时表现出显著靶点选择性和高亲和力,并具有良好的口服生物利用度。
- YX0798口服给药(5 mg/kg每日)在体内产生有效抗肿瘤活性,并显示克服治疗耐药的效力。
- 机制上,YX0798下调短寿命癌蛋白c-MYC和促生存蛋白髓细胞白血病序列1(MCL-1),破坏细胞周期并导致转录组重编程,最终引起细胞死亡。
- YX0798有潜力与临床药物联合使用以提高疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nongenetic transcription evolution has been increasingly explored and recognized to drive tumor cell progression and therapeutic resistance. As the regulation hub of transcription machinery, cyclin-dependent kinase 9 (CDK9) is the gatekeeper of RNA polymerase II transcription, and CDK9 dysfunction results in transcriptomic reprogramming and tumor cell progression. We recently reported that the heat shock protein 90 (HSP90)-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma (MCL) through transcriptomic reprogramming. We also showed that targeting CDK9 by AZD4573 and enitociclib is a safe and effective treatment in preclinical Mantle Cell Lymphoma (MCL) models, supporting CDK9 as a valid therapeutic target for MCL. However, current CDK9 inhibitors (CDK9is) under therapeutic development have room for improvement due to limited target selectivity and oral bioavailability. To this end, YX0798 was discovered to be a novel CDK9i through structural optimization. YX0798 demonstrated remarkable target selectivity and high affinity in binding to CDK9. Furthermore, YX0798 showed good oral bioavailability. YX0798, when administrated orally (5 mg/kg daily), led to an efficacious antitumor activity in vivo and showed the potency in overcoming therapeutic resistance. Mechanistically, YX0798 downregulated the short-lived oncoprotein c-MYC and prosurvival protein myeloid cell leukemia sequence 1 (MCL-1) as a common mechanism of CDK9 inhibition. Moreover, YX0798 disrupted the cell cycle and resulted in transcriptomic reprogramming, eventually leading to cell death. Furthermore, YX0798 has the potential to be used in combination therapy with clinical agents to improve treatment efficacy. Together, these data demonstrate that YX0798 has oral bioavailability, exquisite selectivity, and antitumor potency that results from driving transcription reprogramming toward tumor cell killing.
引用
- Jiang V, Xue Y, Kim H, et al. YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma. Blood Adv. 2025. PMID: 40690748. doi:10.1182/bloodadvances.2025016511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。